BMJ  2004;328:1513 (26 June), doi:10.1136/bmj.328.7455.1513-a

News

GlaxoSmithKline to publish clinical trials after US lawsuit

London

The first 150 words of the full text of this article appear below.

The world's second largest pharmaceutical company, GlaxoSmithKline, is to publish summaries of the results of all its clinical trials on its website once a product has been launched.

GlaxoSmithKline said it has been considering the move for several months now, but it follows on the heels of a US lawsuit, filed by Eliot Spitzer, New York state's attorney general, earlier this month.

Mr Spitzer alleged the company engaged in "repeated and persistent fraud" for concealing the results of clinical studies for its antidepressant paroxetine; these suggested the drug was ineffective and unsafe in treating depression in children and adolescents (12 June, p 1395).

Mr Spitzer also had an internal memo (dated 1998) from GlaxoSmithKline's predecessor company, SmithKlineBeecham, which said that it would be "commercially unacceptable" to admit the results. This document was published in the Canadian Medical Association's journal, CMAJ, earlier this year and reported in the BMJ . . . [Full text of this article]

-->
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Government regulation is needed to prevent biased under-reporting of clinical trials

Iain Chalmers
BMJ 2004 329: 462. [Extract] [Full Text]

GlaxoSmithKline faces US lawsuit over concealment of trial results

Owen Dyer
BMJ 2004 328: 1395. [Extract] [Full Text] [PDF]

GlaxoSmithKline staff told not to publicise ineffectiveness of its drug

David Spurgeon
BMJ 2004 328: 422. [Extract] [Full Text] [PDF]

Correction to a correction: Salt poisoning
BMJ 2003 327: 422. [Full Text] [PDF]

This article has been cited by other articles:

• Wager, E., Abbasi, K. (2009). Medical editors and trial reporting: A betrayal of patient care. JRSM 102: 4-5 [Full text]  
• DeAngelis, C. D. (2006). The Influence of Money on Medical Science. JAMA 296: 996-998 [Full text]  
• Littlejohns, P., Chalkidou, K. (2006). Evidence for health policy. Journal of Research in Nursing 11: 110-117  
• Fontanarosa, P. B, DeAngelis, C. D (2006). JAMA's policy on industry sponsored studies. BMJ 332: 177-177 [Full text]  
• Fontanarosa, P. B., DeAngelis, C. D. (2005). Conflicts of Interest and Independent Data Analysis in Industry-Funded Studies--Reply. JAMA 294: 2576-2577 [Full text]  
• Abbasi, K. (2005). Pills, thrills, and bellyaches. BMJ 330: - [Full text]  
• Rennie, D. (2004). Trial Registration: A Great Idea Switches From Ignored to Irresistible. JAMA 292: 1359-1362 [Full text]  
• Chalmers, I. (2004). Government regulation is needed to prevent biased under-reporting of clinical trials. BMJ 329: 462-462 [Full text]  
• Wessely, S., Kerwin, R. (2004). Suicide Risk and the SSRIs. JAMA 292: 379-381 [Full text]  
• Herxheimer, A. (2004). Open access to industry's clinically relevant data. BMJ 329: 64-65 [Full text]  

Rapid Responses:

Read all Rapid Responses

An ethicless industry

John R. Polito
bmj.com, 26 Jun 2004 [Full text]

Regulation is needed to prevent biased under-reporting of clinical trials

Iain Chalmers
bmj.com, 26 Jun 2004 [Full text]

Withholding negative results from subjects

Mark Hochhauser, Ph.D.
bmj.com, 27 Jun 2004 [Full text]

Online poll

Find out more>>